CFTC Asserts Authority Over Prediction Markets Amid Insider Trading Concerns 
Chime Forecasts Strong 2026 Revenue Growth, Shares Jump on Profit Outlook 
Netflix Declines to Raise Bid for Warner Bros. Discovery Amid Competing Paramount Skydance Offer 
Anthropic Refuses Pentagon Request to Remove AI Safeguards Amid Defense Contract Dispute 
Panama Investigates CK Hutchison’s Port Unit After Court Voids Canal Contracts 
Domino’s Pizza Enterprises Shares Plunge 16% After Weak Same-Store Sales Update 
Trump Pushes Tech Giants to Build Power Plants to Offset AI Data Center Energy Costs 
Nvidia Earnings Beat Expectations as AI Demand Surges, Stock Rises on Strong Revenue Outlook 
Woolworths Shares Surge as First-Half Profit Beats Forecasts and Full-Year Guidance Raised 
Coupang Faces Fallout from Data Breach and Rising Competition in South Korea’s E-Commerce Market 
Flare, Xaman Roll Out One-Click DeFi Vault for XRP Yield via XRPL Wallets 
Lynas Rare Earths Shares Surge on Strong Half-Year Earnings and Rising Global Demand 
Nintendo Share Sale: MUFG and Bank of Kyoto to Sell Stakes in Strategic Unwinding 
Coupang Reports Q4 Loss After Data Breach, Revenue Misses Estimates 
Hyundai Motor Group to Invest $6.26 Billion in AI Data Center, Robotics and Renewable Energy Projects in South Korea 
Toyota Plans $19 Billion Share Sale in Major Corporate Governance Reform Move 
OpenAI Hires Former Meta and Apple AI Leader Ruomin Pang Amid Intensifying AI Talent War 
LA JOLLA, Calif., Jan. 23, 2018 -- via Network NewsWire – INmune Bio, Inc., a cancer immunotherapy company focused on developing therapies that harness the patient’s innate immune system to attack their cancer, today announced that company CEO and President RJ Tesi, M.D., will present at NobleCon14, NOBLE Capital Markets’ 14th annual investor conference, at the W Hotel in Fort Lauderdale, Florida, on January 29 at 10:30 a.m. Eastern Standard Time.
A high-definition video webcast of the presentation will be available the following day on the Company's website, www.inmunebio.com, and as part of a complete catalog of presentations available at Noble Capital Markets’ websites: www.noblecapitalmarkets.com and www.noblecapitalmarkets.com. A Microsoft Silverlight viewer is required (a free download from the presentation link) to participate. The webcast and presentation will be archived on the Company's website and on the Noble websites for 90 days following the event.
About INmune Bio: INmune Bio, Inc. is a private clinical-stage biotechnology company developing therapies targeting the innate immune system in cancer. INmune Bio is developing two products platforms that reengineer the patient’s innate immune system’s response to their cancer, INkmune and INB03. INKmune is an NK cell therapeutic that primes the patient’s NK cells to attack their cancer. INB03 inhibits myeloid derived suppressor cells, which often cause resistance to immunotherapy, such as anti-PD1 checkpoint inhibitors. INmune Bio’s product platforms target residual disease and utilize a precision medicine approach for treatment of a wide variety of hematologic malignancies and solid tumors. To learn more, please visit www.inmunebio.com.
About Noble Capital Markets, Inc.: Noble Capital Markets, established in 1984, is an equity research-driven, full-service investment and merchant banking boutique focused on the healthcare, media & entertainment, technology, transportation & logistics and natural resources sectors. The company has offices in Boca Raton, New York, Boston and St. Louis. In addition to NobleCon, an annual multi-sector investor conference, and the Media, Finance & Investor Program, produced in partnership with the National Association of Broadcasters (NAB) and held each spring in Las Vegas, Noble hosts numerous “non-deal” corporate road shows throughout the year across the United States and Canada. Members: FINRA, SIPC, MSRB. www.noblecapitalmarkets.com
INmune Bio Contact:
David Moss, CFO
(858) 964-3720
[email protected]
www.inmunebio.com
